Edgewise Therapeutics (EWTX) Form 3 Edgewise Therapeutics / Alan J Russell ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Russell Alan J

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

3145 COLORADO AVE.

(Street)

BOULDER CO 80303

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/25/2021

3. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	264,100	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	06/27/2032	Common Stock	1,531,780	0.18	D
Stock Option (Right to Buy)	(2)	08/08/2027	Common Stock	147,585	0.18	D
Stock Option (Right to Buy)	(3)	08/30/2028	Common Stock	155,352	0.45	D
Stock Option (Right to Buy)	(4)	11/14/2029	Common Stock	227,332	0.64	D
Stock Option (Right to Buy)	(5)	09/01/2030	Common Stock	190,137	0.71	D
Stock Option (Right to Buy)	(6)	12/15/2030	Common Stock	475,183	1.93	D

Explanation of Responses:

1. 1/48th of the shares subject to the option became vested and exercisable on July 27, 2017 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

2. 1/4th of the shares subject to the option became vested and exercisable on July 27, 2018 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.

3. 1/48th of the shares subject to the option became vested and exercisable on September 10, 2018 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

4. 1/48th of the shares subject to the option became vested and exercisable on November 16, 2019 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

5. 1/48th of the shares subject to the option became vested and exercisable on October 2, 2020 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

6. 1/48th of the shares subject to the option became vested and exercisable on January 30, 2021 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ John R. Moore Attorney-in-Fact for Alan F Russell	03/25/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.